Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Virios Therapeutics, Inc. (trading symbol: VIRI) on June 15, 2023. The filing details the voting results for three proposals submitted to shareholders. Note: The request metadata referenced "Dogwood Therapeutics, Inc.," but the source document explicitly identifies the registrant as Virios Therapeutics, Inc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting outcomes.
Material Changes and Voting Results
Shareholders representing 53.76% of the voting power attended the meeting. The following outcomes were recorded:
- Proposal 1 (Election of Directors): Approved. Six of seven nominees were elected with significant "For" votes. Richard J. Whitley, M.D., received 4,050,497 "For" votes but also 1,415,334 "Withheld" votes, yet was still declared elected.
- Proposal 2 (Ratification of Auditors): Approved. FORVIS, LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2023, with 9,571,787 "For" votes.
- Proposal 3 (Reverse Stock Split): Not Approved. The proposal to amend the Certificate of Incorporation to effect a reverse stock split (ratio between 1-for-2 and 1-for-25) failed to receive the required majority. It received 9,011,430 "For" votes against 720,787 "Against" votes.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, or specific risk factors beyond the implication that the company sought a reverse stock split, which was rejected by shareholders. No unusual items or contingencies were disclosed in this specific report.
Investor Verification Checklist
- Verify the current status of the Board of Directors following the election results.
- Confirm the company's capital structure and share count, noting the rejection of the reverse stock split.
- Review subsequent filings for any updated financial guidance or strategic shifts following the failed stock split vote.
- Check the company's liquidity position in the most recent 10-Q or 10-K, as this 8-K contains no financial data.